MY194694A - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents

Method and composition for treating cancer or skin lesion using a vaccine

Info

Publication number
MY194694A
MY194694A MYPI2018001489A MYPI2018001489A MY194694A MY 194694 A MY194694 A MY 194694A MY PI2018001489 A MYPI2018001489 A MY PI2018001489A MY PI2018001489 A MYPI2018001489 A MY PI2018001489A MY 194694 A MY194694 A MY 194694A
Authority
MY
Malaysia
Prior art keywords
vaccine
composition
treating cancer
skin lesion
cell carcinoma
Prior art date
Application number
MYPI2018001489A
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of MY194694A publication Critical patent/MY194694A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.
MYPI2018001489A 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine MY194694A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
MY194694A true MY194694A (en) 2022-12-15

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001489A MY194694A (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Country Status (16)

Country Link
EP (1) EP3419661A4 (en)
JP (3) JP2019506435A (en)
KR (1) KR102873848B1 (en)
CN (1) CN108883168A (en)
AU (1) AU2017223970B2 (en)
BR (1) BR112018067550A2 (en)
CA (1) CA3015519A1 (en)
CL (1) CL2018002438A1 (en)
CO (1) CO2018009205A2 (en)
HK (1) HK1256935A1 (en)
IL (1) IL261340B2 (en)
MX (1) MX2018010338A (en)
MY (1) MY194694A (en)
SG (1) SG11201807080UA (en)
WO (1) WO2017147475A1 (en)
ZA (1) ZA201805679B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (en) * 2019-07-19 2024-04-09 神州细胞工程有限公司 Chimeric human papillomavirus type 11 L1 protein
PL4225351T1 (en) * 2020-10-12 2023-12-11 Hpvvax, Llc Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
KR20250089555A (en) * 2022-10-31 2025-06-18 파이로자스 인크 Immunotherapeutic compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN107252489A (en) * 2009-04-13 2017-10-17 法国健康和医学研究院 HPV particles and application thereof
CN101890160B (en) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 Multivalent recombinant human papilloma virus vaccine and application thereof
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
JP2014516075A (en) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー Use of metallocene compounds for the treatment of cancer
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) * 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine
CN120939216A (en) * 2014-01-13 2025-11-14 贝勒研究院 New vaccines against HPV and HPV-related diseases
CN107001430A (en) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 Cancer and cutaneous lesions treatment

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
BR112018067550A2 (en) 2019-10-01
WO2017147475A1 (en) 2017-08-31
EP3419661A4 (en) 2019-10-23
JP2021155448A (en) 2021-10-07
JP7732784B2 (en) 2025-09-02
CO2018009205A2 (en) 2018-09-20
IL261340A (en) 2018-11-29
KR102873848B1 (en) 2025-10-17
JP2023110038A (en) 2023-08-08
IL261340B2 (en) 2023-07-01
EP3419661A1 (en) 2019-01-02
MX2018010338A (en) 2018-11-09
AU2017223970B2 (en) 2022-01-27
SG11201807080UA (en) 2018-09-27
CA3015519A1 (en) 2017-08-31
CN108883168A (en) 2018-11-23
ZA201805679B (en) 2019-11-27
AU2017223970A1 (en) 2018-09-13
JP2019506435A (en) 2019-03-07
KR20180112043A (en) 2018-10-11
CL2018002438A1 (en) 2019-01-04
HK1256935A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
AU2015329999B2 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
HK1246183A1 (en) Hpv vaccines
HK1246230A1 (en) Human fibrolamellar hepatocellular carcinomas (hfl-hccs)
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
WO2014153082A3 (en) Systems and methods for treating prostate cancer
WO2014106492A3 (en) Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2023011105A (en) Optimized oncolytic viruses and uses thereof.
EP4552698A3 (en) Methods of treating prostate cancer
IN2014MU00303A (en)
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2018013340A (en) Therapeutic hpv vaccine combinations.
HK1250626A1 (en) Combination treatments with seribantumab
MY194694A (en) Method and composition for treating cancer or skin lesion using a vaccine
PH12017500754A1 (en) Cancer and skin lesion treatment
ZA202305254B (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
MX2023004285A (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient.
PH12015502086A1 (en) Ablative immunotherapy
NZ742470A (en) Combination therapy for cancer
IL237622B (en) Composition and method of using medicament for treatment of cancers and tumors
劉漢邦 et al. Alveolar soft part sarcoma of tongue-A rare case report